Effect of denosumab combined with vertebroplasty in patients with thoracic compression fractures
Objective This study aimed to investigate the effect of denosumab combined with vertebroplasty in the treatment of thoracolumbar vertebral compression fractures.Methods Sixty patients with thoracolumbar compression fractures who underwent vertebroplasty in our hospital from January 2022 to January 2024 were retrospectively selected as the study subjects.They were divided into an observation group and a control group,with 30 cases in each group,according to the postoperative anti-osteoporosis program.The control group was treated with vertebroplasty combined with routine calcium,and the observation group was treated with denosumab,vertebroplasty,and calcium.Changes in the Oswsetry dysfunction index(ODI),Japanese Orthopedic Society Low Back Pain Function Rating Scale(M-JOA),visual analog pain rating scale(VAS),kyphotic angle,anterior vertebrae height,bone mineral density of the injured vertebrae,treatment effectiveness,and the rate of refracture during treatment were observed and compared between the two groups one month after continuous intervention.Results After rehabilitation treatment,certain clinical expectations were achieved,and the effective rate of the observation group was significantly higher than that of the control group(P＜0.05).VAS scores were significantly reduced in both groups,and the reduction was greater in the observation group(P＜0.05).ODI scores were significantly reduced,and M-JOA scores were increased in both groups(P＜0.05).The improvement(increase or decrease)in the observation group was significantly better than in the control group(P＜0.05).Improvements in the anterior height and kyphotic angle of the injured vertebrae in the observation group were significantly better than in the control group(P＜0.05).The improved frontal height,kyphotic angle,and bone mineral density in the observation group were significantly better than in the control group.The refracture rate in the observation group was significantly lower than in the control group,and the difference was statistically significant(P＜0.05).Conclusion Denosumab combined with vertebroplasty significantly improved the ODI in patients with thoracolumbar compression fractures.The treatment also effectively improved the therapeutic effect in patients and lumbar function,increased bone mineral density,and reduced secondary fractures.
NETL
NSTL
万方数据
